Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Structure and Function of Platelets

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Vox Sanguinis International Forum on platelet cryopreservation.

Vox sanguinis·2017

Same author

Vox Sanguinis International Forum on platelet cryopreservation: Summary.

Vox sanguinis·2017

Same author

Comparison of haemostatic function of PAS-C-platelets vs. plasma-platelets in reconstituted whole blood using impedance aggregometry and thromboelastography.

Vox sanguinis·2017

Same author

Serum eye drops: a survey of international production methods.

Vox sanguinis·2017

Same author

Alternatives in blood operations when choosing non-DEHP bags.

Vox sanguinis·2017

Same author

Experiences with semi-routine production of riboflavin and UV-B pathogen-inactivated platelet concentrates in three blood centres.

Vox sanguinis·2016

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Platelet additive solutions: a future perspective.

P F van der Meer¹

¹Sanquin Blood Bank North West region, Plesmanlaan 125, Amsterdam, The Netherlands. p.vandermeer@sanquin.nl

Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine

|April 19, 2008

Summary

This summary is machine-generated.

Platelet additive solutions (PASs) offer benefits for platelet concentrate quality and patient outcomes. Recent advancements in PAS formulations, including key electrolytes and buffers, enhance platelet storage time and quality, though further clinical validation is needed.

More Related Videos

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Related Experiment Videos

Last Updated: Jul 5, 2026

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Area of Science:

Blood banking and transfusion medicine
Biomaterials and regenerative medicine
Hematology

Background:

Platelet additive solutions (PASs) were developed to improve platelet concentrate (PC) quality and patient outcomes.
Early PAS formulations faced challenges like reduced platelet yield, shorter storage, and lower in-vivo efficacy compared to plasma storage.
Continuous reformulation aims to overcome these limitations and optimize platelet preservation.

Purpose of the Study:

To review the evolution and optimization of PAS formulations for platelet storage.
To highlight key components and their impact on platelet quality, storage duration, and clinical effectiveness.
To identify areas for future research and development in PAS technology.

Main Methods:

Review of existing literature on PAS development and formulation.
Analysis of the biochemical effects of PAS components (nutrients, buffers, electrolytes) on platelet function and viability.
Comparison of in-vitro and in-vivo study findings regarding PAS efficacy.

Main Results:

PAS formulations have evolved significantly, incorporating essential electrolytes like potassium and magnesium to improve platelet activation and storage.
Optimized PAS can achieve storage times comparable to or exceeding those in plasma, with improved platelet quality.
Emerging formulations explore bicarbonate buffering and additives like L-carnitine, with a trend towards significantly reducing residual plasma content.

Conclusions:

PASs represent a viable alternative to plasma for platelet storage, offering extended shelf-life and maintained quality.
Key advancements include electrolyte inclusion and optimized buffering systems, addressing earlier limitations.
Further clinical studies are crucial to fully substantiate the in-vitro findings and confirm the long-term clinical benefits of advanced PAS formulations.